DOCSLIB.ORG

Develop* Genetically Modified Organisms in Containment Under Section 40(1)(B) of the HSNO Act 1996 (Excluding Rapid Assessment)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Develop* Genetically Modified Organisms in Containment Under Section 40(1)(B) of the HSNO Act 1996 (Excluding Rapid Assessment) Application to Develop* genetically modified organisms in containment Under section 40(1)(b) of the HSNO Act 1996 (excluding rapid assessment) *“Develop” includes developing, fermenting and regenerating genetically modified organisms BP House 20 Customhouse Quay PO Box 131, Wellington Phone: 04-916 2426 Fax: 04-914 0433 Email: [email protected] Web: www.ermannz.govt.nz ER-AF-N03-4 09/09 Please note This application form covers the development of genetically modified organisms that: 1. Do not meet Category A and/or B experiments as defined in the HSNO (Low- Risk Genetic Modification) Regulations 2003; 2. Occur either in a containment structure (i.e. laboratory) or outdoors within a containment facility; or 3. Otherwise cannot undergo a rapid assessment for low-risk genetic modification. Any extra material that does not fit in the application form must be clearly labelled, cross-referenced, and included as appendices to the application form. Commercially sensitive information must be collated in a separate appendix. You should justify why you consider the material commercially sensitive, and make sure it is clearly labelled as such. If technical terms are used in the application form, simply explain these terms in the Glossary (Section 8 of this application form). Unless otherwise indicated, all sections of this form must be completed for the application to progress. Applicants must sign the application form and enclose the correct application fee (including GST). The application fee can be found in our published Schedule of Fees and Charges on the ERMA New Zealand website. We are unable to process applications that do not contain the correct application fee. An electronic and paper copy of the final completed form must be submitted. If you have any queries regarding the information required or would like to discuss your draft application form, please contact a New Organisms Advisor at ERMA New Zealand. This form was approved by the Chief Executive of ERMA New Zealand on 22 September 2009. This form replaces all previous versions. Page 2 of 19 Section 1: Application details a) Application title Genetic modification of animal and human cell lines for research and teaching purposes b) Organisation name University of Otago c) Postal Address Department of Microbiology and Immunology, University of Otago P O Box 56 Dunedin Page 3 of 19 Section 2: Summary of application a) Provide a plain English summary of this application including: . Explain the purpose of your research in the context of your organisation’s history and goals. The purpose of the application (e.g. what is the research you wish to perform and why do you consider that it is important? what are the benefits of this research?). If there are any alternative methods to achieve the aims of this research, explain why you wish to perform the research this way. Describe the project you wish to undertake (section 40(2)(a)(ii) of the HSNO Act). Are you aware of any possible adverse effects of the organism on the environment? If so, any potential mitigation measures? . Where do you intend to conduct these activities? Are there specific location(s) or are you seeking approval for all of New Zealand? . How do other legislative requirements apply to your proposed activities? (e.g. the Resource Management Act, the Medicines Act. If this application is for a development outdoors within a containment facility, discuss why your activities are not “field testing” activities for the purpose of the HSNO Act. If technical terms are used here or elsewhere in the application, add simple explanations for these terms in the Glossary (Section 8 of this application form). The University of Otago is a research-intensive university. This application seeks approval to genetically modify animal and human cell lines to provide researchers and students with tools to explore the role and function of genes. These develpoments will underpin research into distinct areas of biology but are unified by their use of standard laboratory methodology, including the use plasmids and replication-deficient viral vectors, to transfer nucleic acids into animal or human cell lines. The ability to genetically modify these cell lines in this way will help researchers to determine gene function, and more specifically how individual genes and groups of genes influence biological processes in vivo. This research is designed to generate and apply new knowledge of processes involved in: 1. Cell growth, metabolism, differentiation and development; 2. Biological responses to environmental and chemical stress; 3. Host-pathogen and host-commensal interactions; and 4. The causation of disease The animal and human cell lines to be modified will be established cell lines obtained from commercial sources or from reputable scientific laboratories, or will be primary cell lines developed with the approval of an appropriate Ethics Committee. The cell lines may include embryonic stem cell and induced pluripotent stem cell lines of animal species and induced pluripotent stem cell lines derived from humans, but will not include embryonic stem cell lines derived from humans. In many cases the genetic manipulation will involve a complete gene sequence from one species being introduced into a cell line derived from the same or a different species to enable changes in the biology or biochemistry of the recipient cell line to be correlated with the function of the transferred gene. In some cases DNA sequences will be introduced into a cell line to investigate function by silencing endogenous genes within that host. A further scientific goal of this research involves expression of genes by modified cell lines to allow purification and biochemical characterisation of recombinant proteins, or to produce replication-deficient viral vectors. In other cases, “reporter” genes will be introduced into a cell line in order to allow the expression of a gene within it to be monitored by various techniques (e.g. fluorescent microscopy for cell lines expressing green fluorescent protein) that detect expression of the reporter gene. The broad nature of these studies requires approval to modify a wide range of animal and Page 4 of 19 human cell lines with a variety of genes from different organisms. However in all cases the modifications will be restricted by virtue of the fact that genes transferred to any cell line will not lead to the production of infectious particles such as prions or replication-competent viruses and will not increase the risk of the cell lines to humans. The cell lines are completely reliant on human intervention for survival and would not survive outside of controlled conditions in the laboratory. Therefore, the nature of containment is such that the risk of escape and subsequent infection is negligible. The benefits from the development of these cell lines will be to add to the body of scientific knowledge of processes involved in growth, metabolism, differentiation, disease and response to stress, and knowledge that may lead to the development of new treatments or diagnostic tools for various diseases of humans and animals. b) Provide a short summary statement of the purpose of this application to be used on ERMA New Zealand’s public register This statement must be a maximum of 255 characters including spaces and punctuation. If native or human genetic material directly obtained from New Zealanders is to be used, include this information here. Sufficient details must be provided to enable the Authority to provide the information required in the register under section 20(2)(c) of the HSNO Act. To develop genetically modified cultured animal and human cell lines for research and teaching purposes to generate knowledge of processes involved in growth, metabolism, differentiation, development, stress response and disease. Page 5 of 19 Section 3: The proposed organism(s) to be developed Section 2(1) of the HSNO Act defines what “identification” is. You must provide sufficient information to fulfill the criteria listed in the HSNO Act to enable the Authority to uniquely identify the organism in the register (as required in section 20(2)(b) of the HSNO Act). As per sections 40(2)(a)(i)-(iv) of the HSNO Act, you must: . Identify the new organism(s) (at the appropriate taxonomic level). Hint — you could start by discussing the characteristics of the host organism and then how the proposed genetic modifications are expected to alter these characteristics. Describe the project and the experimental procedures to be used. Provide details of biological material to be used. Provide details of the expression of foreign nucleic acid (if relevant). You must describe the biological characteristics of the new organism(s). The information should be relevant to: . The hazardous nature of the organism(s) that you are aware of. For example, is it a bacterium that can cause disease in plants or humans? Will the modifications enhance the pathogenicity of a microorganism? . Which of its characteristics may enable it to escape from containment? For example, can it produce air-disseminated spores? Can it dig under fences? Can it jump or fly over high fences? . The ability of the organism(s) to form an undesirable self-sustaining population and how easy such a population could be eradicated (section 43(b) of the HSNO Act). Organisms A. Animal cell lines derived from the species listed in Appendix 1. B. Human cell lines. The animal and human cell lines to be modified will be established cell lines obtained from commercial sources or from reputable scientific laboratories, or will be primary cell lines. Primary cell lines will be developed with the approval of an appropriate Ethics Committee and following appropriate Maori consultation or will be obtained from commercial sources or from reputable overseas scientific laboratories that developed the lines under ethical approval. The cell lines to be developed may include stem cell lines, including embryonic stem cell lines and induced pluripotent stem cells of animal species and induced pluripotent stem cells derived from humans, but will not include human embryonic stem cell lines.
Load more

Recommended publications
  • Rnai in Primary Cells and Difficult-To-Transfect Cell Lines
    Automated High Throughput Nucleofection® RNAi in Primary Cells and Difficult-to-Transfect Cell Lines Claudia Merz, Bayer Schering Pharma AG, Berlin, Germany; Andreas Schroers, amaxa AG, Cologne, Germany; Eric Willimann, Tecan AG, Männedorf, Switzerland. Introduction Materials & Methods - Workflow Using primary cells for RNAi based applications such as target identification or – validation, requires a highly efficient transfection displaying the essential steps of the automated Nucleofector® Process: technology in combination with a reliable and robust automation system. To accomplish these requirements we integrated the amaxa 1. Transfer of the cells to the Nucleocuvette™ plate, 96-well Shuttle® in a Tecan Freedom EVO® cell transfection workstation which is based on Tecan’s Freedom EVO® liquid handling 2. Addition of the siRNA, (Steps 1 and 2 could be exchanged), platform and include all the necessary components and features for unattended cell transfection. 3. Nucleofection® process, 4. Addition of medium, Count Cells 5. Transfer of transfected cells to cell culture plate for incubation ® Nucleofector Technology prior to analysis. Remove Medium The 96-well Shuttle® combines high-throughput compatibility with the Nucleofector® Technology, which is a non-viral transfection method ideally suited for primary cells and hard-to-transfect cell lines based on a combination of buffers and electrical parameters. Nucleocuvette Plate Add Nucleofector +– The basic principle and benefits of the (empty) Solution Cell of interest Gene of interest Nucleofector®
    [Show full text]
  • Widespread Gene Transfection Into the Central Nervous System of Primates
    Gene Therapy (2000) 7, 759–763 2000 Macmillan Publishers Ltd All rights reserved 0969-7128/00 $15.00 www.nature.com/gt NONVIRAL TRANSFER TECHNOLOGY RESEARCH ARTICLE Widespread gene transfection into the central nervous system of primates Y Hagihara1, Y Saitoh1, Y Kaneda2, E Kohmura1 and T Yoshimine1 1Department of Neurosurgery and 2Division of Gene Therapy Science, Department of Molecular Therapeutics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan We attempted in vivo gene transfection into the central ner- The lacZ gene was highly expressed in the medial temporal vous system (CNS) of non-human primates using the hem- lobe, brainstem, Purkinje cells of cerebellar vermis and agglutinating virus of Japan (HVJ)-AVE liposome, a newly upper cervical cord (29.0 to 59.4% of neurons). Intrastriatal constructed anionic type liposome with a lipid composition injection of an HVJ-AVE liposome–lacZ complex made a similar to that of HIV envelopes and coated by the fusogenic focal transfection around the injection sites up to 15 mm. We envelope proteins of inactivated HVJ. HVJ-AVE liposomes conclude that the infusion of HVJ-AVE liposomes into the containing the lacZ gene were applied intrathecally through cerebrospinal fluid (CSF) space is applicable for widespread the cisterna magna of Japanese macaques. Widespread gene delivery into the CNS of large animals. Gene Therapy transgene expression was observed mainly in the neurons. (2000) 7, 759–763. Keywords: central nervous system; primates; gene therapy; HVJ liposome Introduction ever, its efficiency has not been satisfactory in vivo. Recently HVJ-AVE liposome, a new anionic-type lipo- Despite the promising results in experimental animals, some with the envelope that mimics the human immuno- gene therapy has, so far, not been successful in clinical deficiency virus (HIV), has been developed.13 Based upon 1 situations.
    [Show full text]
  • Investigating the Anti-Apoptotic Role of EBV in Endemic Burkitt
    Investigating the anti-apoptotic role of EBV in endemic Burkitt lymphoma by LEAH FITZSIMMONS A thesis submitted to The University of Birmingham for the degree of DOCTOR OF PHILOSOPHY School of Cancer Sciences College of Medical and Dental Sciences The University of Birmingham September 2014 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. Abstract Epstein-Barr virus (EBV) has been etiologically associated with Burkitt lymphoma (BL) since its discovery 50 years ago, but despite this long-standing association the precise role of the virus in the pathogenesis of BL remains enigmatic. EBV can be lost spontaneously from EBV-positive BL cell lines, and these EBV-loss clones have been reported to exhibit increased sensitivity to apoptosis. We have confirmed and extended those observations and report that sporadic loss of EBV from BL cells is consistently associated with enhanced sensitivity to apoptosis-inducing agents and conversely, reduced tumorigenicity in vivo. Importantly, reinfection of EBV-loss clones with EBV can restore apoptosis protection, although surprisingly, individual Latency I genes cannot. We also used inducible pro-apoptotic BH3 ligands to investigate Bcl-2-family dependence in BL clones as well as profiling gene expression changes in response to apoptosis induction in EBV- positive versus EBV-loss clones.
    [Show full text]
  • Efficient Genome Editing in Multiple Salmonid Cell Lines Using Ribonucleoprotein Complexes
    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.03.022038; this version posted April 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Efficient genome editing in multiple salmonid cell lines using ribonucleoprotein complexes 2 Remi L. Gratacap1*, Ye Hwa Jin1*, Marina Mantsopoulou1, and Ross D. Houston1** 3 1. The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, 4 Midlothian EH25 9RG, United Kingdom 5 *These authors contributed equally to this work 6 ** Corresponding author: [email protected] 7 ORCID ID: 8 Remi Gratacap: 0000-0001-9853-2205 9 Ye Hwa Jin: 0000-0003-2736-2493 10 Ross Houston: 0000-0003-1805-0762 11 Abstract 12 Infectious and parasitic diseases have major negative economic and animal welfare impacts on 13 aquaculture of salmonid species. Improved knowledge of the functional basis of host response and 14 genetic resistance to these diseases is key to developing preventative and treatment options. Cell 15 lines provide a valuable model to study infectious diseases in salmonids, and genome editing using 16 CRISPR provides an exciting avenue to evaluate the function of specific genes in those systems. 17 While CRISPR/Cas9 has been successfully performed in a Chinook salmon cell line (CHSE-214), 18 there are no reports to date of editing of cell lines derived from the most commercially relevant 19 salmonid species Atlantic salmon and rainbow trout, which are difficult to transduce and therefore 20 edit using lentivirus-mediated methods.
    [Show full text]
  • Food and Drug Law Journal
    FOOD AND DRUG LAW JOURNAL EDITOR IN CHIEF Judy Rein EDITORIAL ADVISORY BOARD CHAIR VICE CHAIR FACULTY ADVISOR Laurie Lenkel Robert Giddings Joseph A. Page FDA – OC Hutchison PLLC Georgetown University Law Center ________________________________ Anthony Anscombe James Flaherty Francis Palumbo Sedgwick LLP Fresenius Medical University of Maryland School of Pharmacy Peter Barton Hutt Abraham Gitterman Covington & Burling Arnold & Porter LLP Sandra Retzky FDA – CTP Barbara Binzak Kimberly Gold Blumenfeld Norton Rose Fulbright Joan Rothenberg Buchanan Ingersoll & LLP FDA - CFSAN Rooney PC John Johnson Jodi Schipper Catherine Clements FDA Imports FDA – CDER Express Scripts Alan Katz Christopher van Gundy Kellie Combs toXcel, LLC Keller and Heckman Ropes & Gray LLP Sara Koblitz James Woodlee Nathan Cortez Fish & Richardson Kleinfeld Kaplan & Becker LLP Southern Methodist University Valerie Madamba Emily Wright Blue Apron Pfizer Brian Dahl Dahl Compliance Alan Minsk Kimberly Yocum Consulting LLC Arnall Golden Gregory TC Heartland LLC LLP Sandra dePaulis Lowell Zeta FDA – CVM Nicole Negowetti Hogan Lovells The Good Food Ian Fearon Institute Patricia Zettler British American Tobacco Georgia State James O’Reilly University Law School University of Cincinnati OFFICERS OF THE FOOD AND DRUG LAW INSTITUTE CHAIR: Allison M. Zieve, Public Citizen Litigation Group VICE CHAIR: Jeffrey N. Gibbs, Hyman, Phelps & McNamara, P.C. TREASURER: Frederick R. Ball, Duane Morris LLP GENERAL COUNSEL/SECRETARY: Joy J. Liu, Vertex Pharmaceuticals IMMEDIATE PAST CHAIR: Sheila Hemeon-Heyer, Heyer Regulatory Solutions LLC PRESIDENT & CEO: Amy Comstock Rick GEORGETOWN UNIVERSITY LAW CENTER STUDENT EDITOR IN CHIEF Dana Shaker STUDENT MANAGING EDITORS Jacob Klapholz Christine Rea STUDENT NOTES EDITOR SYMPOSIUM EDITOR Lauren Beegle Alexander P.
    [Show full text]
  • The Art of Transfection (Poster / Pdf)
    TRANSDUCTION NON-VIRAL TRANSFECTION Transduction is the process of using vectors including retroviruses, lentiviruses, adenoviruses, PACKAGE DELIVERY: Chemical Chemical transfection adeno-associated viruses, or hybrids to deliver genetic payloads into cells. Generally, a plasmid transfection reagent containing mRNA carrying genes flanked by viral sequences is first transfected into a producer cell with other reagent virus-associated (packaging) plasmids. In the producer cells, virions form that contain the gene The Art of Transfection of interest. For safety, no plasmid used in the process contains all of the necessary sequences Inserting genetic material into mammalian and insect cells without killing them can be a challenge, CHEMICAL TRANSFECTION for virion formation, and only the plasmid carrying the gene of interest contains signals that but scientists have developed several ways to perform this intricate task. Transfection is the process of Functional proteins or allow it to be packaged into virions. Researchers then extract, purify, and use the virions from Complexation structural components released Chemical carriers represent the most straightforward and widespread tools for gene delivery the producer cells to insert DNA into other cells to stably or transiently express the DNA of introducing nucleic acids (plasmid DNA or messenger, short interfering, or micro RNA) into a cell. from cell or into cytoplasm experiments in mammalian cells. Chemical transfection experiments follow a simple workflow and interest. The transferred genetic material, which lacks viral genes, cannot generate new viruses. Researchers accomplish this with nonviral methods (chemical or physical transfection), or with viral provide high efficiency nucleic acid delivery for the most commonly used cells as well as many methods, commonly referred to as transduction.
    [Show full text]
  • Ep001645626b1*
    (19) *EP001645626B1* (11) EP 1 645 626 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12N 5/06 (2006.01) A61K 48/00 (2006.01) 12.09.2007 Bulletin 2007/37 (21) Application number: 05255932.5 (22) Date of filing: 23.09.2005 (54) Cell line Zelllinie Lignée cellulaire (84) Designated Contracting States: (56) References cited: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR WO-A-01/66781 WO-A-97/10329 HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI US-A- 5 580 777 US-A- 5 770 414 SK TR US-A1- 2003 143 737 (30) Priority: 30.09.2004 GB 0421753 • LITTLEWOOD T D ET AL: "A MODIFIED 23.11.2004 GB 0425767 OESTROGEN RECEPTOR LIGAND-BINDING 20.12.2004 GB 0427830 DOMAIN AS AN IMPROVED SWITCH FOR THE REGULATION OF HETEROLOGOUS PROTEINS" (43) Date of publication of application: NUCLEIC ACIDS RESEARCH, OXFORD 12.04.2006 Bulletin 2006/15 UNIVERSITY PRESS, SURREY, GB, vol. 23, no. 10, 1995, pages 1686-1690, XP002925103 ISSN: (73) Proprietor: Reneuron Limited 0305-1048 Guildford, • GRAY J A ET AL: "PROSPECTS FOR THE Surrey GU2 7AF (GB) CLINICAL APPLICATION OF NEURAL TRANSPLANTATION WITH THE USE OF (72) Inventors: CONDITIONALLY IMMORTALIZED • Sinden, John NEUROEPITHELIAL STEM CELLS" Guildford, PHILOSOPHICAL TRANSACTIONS. ROYAL Surrey GU2 7AF (GB) SOCIETY OF LONDON. BIOLOGICAL SCIENCES, • Pollack, Kenneth ROYAL SOCIETY, LONDON, GB, vol. 354, no. Guildford, 1388, August 1999 (1999-08), pages 1407-1421, Surrey GU2 7AF (GB) XP000865924 ISSN: 0962-8436 • Stroemer, Paul Guildford, Remarks: Surrey GU2 7AF (GB) Thefilecontainstechnicalinformationsubmittedafter the application was filed and not included in this (74) Representative: Jappy, John William Graham specification Gill Jennings & Every LLP Broadgate House 7 Eldon Street London EC2M 7LH (GB) Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Micro-RNA Modulation of Insect Virus Replication Verna Monsanto-Hearne and Karyn N
    Micro-RNA Modulation of Insect Virus Replication Verna Monsanto-Hearne and Karyn N. Johnson* School of Biological Sciences, University of Queensland, Brisbane, Australia. *Correspondence: [email protected] htps://doi.org/10.21775/cimb.034.061 Abstract Saleh, 2012; Xu and Cherry, 2014; Mussabekova Te outcome of virus infection in insects is impacted et al., 2017). Many molecular components medi- by regulation of both host and virus gene expres- ate and are mediated by this host–virus cross-talk, sion. A class of small RNAs called micro-RNAs including microRNAs. (miRNA) have emerged as important regulators of microRNAs (miRNAs) are a large class of highly gene expression that can infuence the outcome of conserved, ≈ 22 nt non-coding RNAs that regulate virus infection. miRNA regulation occurs at a com- gene expression. Compared to the more upstream paratively late stage of gene expression, allowing for regulatory mechanisms such as transcriptional rapid control and fne-tuning of gene expression regulation and chromatin remodelling, regulation levels. Here we discuss the biogenesis of miRNAs by miRNA occurs at a later stage of gene expres- from both host and virus genomes, the interactions sion, allowing for rapid control and fne-tuning of that lead to regulation of gene expression, and the gene expression levels (Chen et al., 2013). Comple- miRNA–mRNA interactions that lead to either mentary binding of at least the seed region (second antivirus or provirus consequences in the course of to eighth nucleotide from the 5′-end) of the ≈ 22 nt virus
    [Show full text]
  • Genetic Engineering: Moral Aspects and Control of Practice
    Journal of Assisted Reproduction and Genetics, VoL 14. No. 6, 1997 NEWS AND VIEWS REPRODUCTIVE HEALTH CARE POLICIES AROUND THE WORLD Genetic Engineering" Moral Aspects and Control of Practice INTRODUCTION outline the concept of gene therapy with regard to the ethical aspects involved. Since the time of Hippocrates, physicians have sought to understand the'mechanisms of disease development for the purposes of developing more HISTORY effective therapy. The application of molecular biol- ogy to human diseases has produced significant The following is a concise review of the history discoveries about some of these disease states. of gene therapy. Extensive reviews can be found Gene transfer involves the delivery to target cells elsewhere (1). The human species has for many of an expression cassette made up of one or more generations practiced genetic manipulation on genes and the sequence controlling their expres- other species. Examples can be seen in the breed- sion. The process is usually aided by a vector that ing of animals and plants for specific intent, such helps deliver the cassette to the intracellular site as, corn, roses, dogs, and horses. The term "genet- where it can function appropriately. Human gene ics" was first used in 1906, and the term "genetic therapy has moved from feasibility and safety stud-. engineering" originated in 1932. Genetic engi- ies to clinical application more rapidly than was neering was then defined as the application of expected. The development of recombinant DNA genetic principles to animal and plant breeding. technology brought science to the brink of curing The term "gene therapy" was adopted to distin- previously untreatable diseases in a relatively short guish itself from the ominous, germ-line perception period of time.
    [Show full text]
  • Agrobacterium Tumefaciens-Mediated Genetic Transformation of the Ect-Endomycorrhizal Fungus Terfezia Boudieri
    G C A T T A C G G C A T genes Technical Note Agrobacterium tumefaciens-Mediated Genetic Transformation of the Ect-endomycorrhizal Fungus Terfezia boudieri 1,2 1, 1 1, Lakkakula Satish , Madhu Kamle y , Guy Keren , Chandrashekhar D. Patil z , Galit Yehezkel 1, Ze’ev Barak 3, Varda Kagan-Zur 3, Ariel Kushmaro 2 and Yaron Sitrit 1,* 1 The Albert Katz International School for Desert Studies, The Jacob Blaustein Institutes for Desert Research, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel; [email protected] (L.S.); [email protected] (M.K.); [email protected] (G.K.); [email protected] (C.D.P.); [email protected] (G.Y.) 2 Avram and Stella Goldstein-Goren Department of Biotechnology Engineering and The Ilse Katz Center for Meso and Nanoscale Science and Technology, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel; [email protected] 3 Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel; [email protected] (Z.B.); [email protected] (V.K.-Z.) * Correspondence: [email protected]; Tel.: +972-8-6472705 Current address: Department of Forestry, North Eastern Regional Institute of Science & Technology, y Nirjuli, Arunachal Pradesh 791109, India. Current address: Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, z Chicago, IL 60612, USA. Received: 23 September 2020; Accepted: 29 October 2020; Published: 30 October 2020 Abstract: Mycorrhizal desert truffles such as Terfezia boudieri, Tirmania nivea, and Terfezia claveryi, form mycorrhizal associations with plants of the Cistaceae family.
    [Show full text]
  • Improving Electrotransfection Efficiency by Post-Pulse Centrifugation
    Gene Therapy (1999) 6, 364–372 1999 Stockton Press All rights reserved 0969-7128/99 $12.00 http://www.stockton-press.co.uk/gt Improving electrotransfection efficiency by post-pulse centrifugation LH Li1,2, P Ross1 and SW Hui1 1Membrane Biophysics Laboratory, Roswell Park Cancer Institute, Buffalo, NY, USA We have demonstrated that the viability of electro- dorf desktop centrifuge. Pelleting improves the cell viability transfected adherent CHO and suspended NK-L, K-562, over the whole range of the NK-L, K-562, L1210 and MC2 L1210 and MC2 cells is improved if pelleting by centrifug- cell concentrations studied. When this pelleting method is ation is performed immediately after pulsing. The protec- applied to load CHO cells with FITC-dextran (41 000 MW), tion effect on cell viability is cell line- and pellet thickness- not only is the success rate close to 100%, but the growth dependent. For forming CHO cell pellets, centrifugation rate is similar to the control, which is far better than the force (300–13 000 g) and duration are not crucial; about conventional electroporation method. Furthermore, the five to 10 cell layers in the pellet provide the optimal protec- transfection efficiency of the five cell lines in pellet is sig- tion effect. NK-L, K-562, L1210 and MC2 cell pellets are nificantly higher than that in suspension. optimally formed by centrifugation at 13 000 g in an Eppen- Keywords: centrifugation pellet; viability; electroporation; electroloading; electrotransfection Introduction method that can improve cell viability is likely to improve electrotransfection efficiency. Electroporation has become a popular method in biotech- Pelleting by centrifugation effectively reduces extra- nology for transferring genetic materials, as well as other cellular volume between cells and leads to reduced biochemicals, such as foreign proteins and drugs, into erythrocyte electrohemolysis by restricting post-pulse cell 1–3 cells.
    [Show full text]
  • ZW Bw Deurholt
    UvA-DARE (Digital Academic Repository) Development of an immortalised human hepatocyte cell line for the AMC Bio- Artificial Liver Deurholt, T. Publication date 2007 Document Version Final published version Link to publication Citation for published version (APA): Deurholt, T. (2007). Development of an immortalised human hepatocyte cell line for the AMC Bio-Artificial Liver. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl) Download date:06 Oct 2021 Development of an immortalised human hepatocyte cell line for the AMC Bio-Artificial Liver Tanja Deurholt Colofon The work described in this thesis was financially supported by: - the European Union - Hep-Art Medical Devices B.V., the Netherlands
    [Show full text]